Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest antibodies Stories

Flu Cure Neutralizes Influenza A
2012-09-12 04:16:04

Michael Harper for redOrbit.com — Your Universe Online One drug maker took to the stage on Monday in San Francisco to announce some very encouraging and positive results at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). According to the results from preclinical studies, Visterra, Inc. may have found a viable preventative drug against Influenza. Called VIS410, this drug is an engineered human antibody which can be used to ward off Influenza...

2012-09-04 10:56:15

Mass spectrometry protein assays that match sensitivity and accuracy of antibody-based clinical tests might speed drug discovery, basic biology research Combining two well-established analytic techniques and adding a twist identifies proteins from blood with as much accuracy and sensitivity as the antibody-based tests used clinically, researchers report this week in Proceedings of the National Academy of Sciences Early Edition online. The technique should be able to speed up development of...

2012-09-04 02:29:09

SHANGHAI and PALO ALTO, Calif., Sept. 4, 2012 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, and Open Monoclonal Technology, Inc. (OMT), an innovator in novel transgenic animals for development of human therapeutic antibodies, today announced that they have entered into an agreement to use OMT's OmniRat(TM) to develop therapeutic...

2012-08-30 02:25:47

MOUNTAIN VIEW, Calif., Aug. 30, 2012 /PRNewswire/ -- A large competitor base and fluid market share has kept the research antibodies market highly competitive despite its maturity. Low entry barriers, large market size, and easy original equipment manufacturer (OEM) opportunities attract a wide variety of companies to this market. As research antibodies vary in quality by company, type, and even lot, customer satisfaction is hard to achieve. This translates to considerable chances for...

2012-08-28 02:29:42

IRVINE, Calif., Aug. 28, 2012 /PRNewswire/ -- GeneTex, Inc., a leading manufacturer of antibodies, has announced that they will be launching a new antibody against HIF1a (hypoxia-inducible factor 1alpha). (Photo: http://photos.prnewswire.com/prnh/20120828/AQ63427) (Logo: http://photos.prnewswire.com/prnh/20111129/LA13485LOGO-b) Hypoxia, a physiological state characterized by reduced oxygen levels, impacts metabolism, angiogenesis, vasodilation and erythropoiesis through the HIF1a...

2012-08-22 12:13:28

As a step toward designing the first effective vaccine against HIV, the virus that causes AIDS, scientists are reporting new insights into how a family of rare, highly potent antibodies bind to HIV and neutralize it – stop it from infecting human cells. The antibodies were isolated from people infected with HIV and work against a wide range of HIV strains. The researchers described the study today at the 244th National Meeting & Exposition of the American Chemical Society, the...

2012-08-16 02:24:58

SOUTH SAN FRANCISCO, Calif., Aug. 16, 2012 /PRNewswire/ -- Trellis Bioscience LLC, a private company discovering and developing novel human antibody therapeutics for the treatment of infectious disease and cancer, has been awarded a Small Business Innovation Research (SBIR) fast-track grant to advance its native human antibody against cytomegalovirus (CMV), CMV345, through preclinical development towards an Investigational New Drug (IND) application filing. The four-year, $3.3 million grant...

2012-08-14 02:29:01

NEWCASTLE, England, August 14, 2012 /PRNewswire/ -- Leica Microsystems announces the introduction of the Novocastra(TM) HD antibody range, 80 clinically important immunohistochemistry antibody clones, spanning 10 anatomical pathologies. Novocastra HD was developed to meet the needs of pathologists and histologists, in terms of menu, diagnostic confidence and workflow. This new 'Highly Definitive' range was created following extensive global market research on customer...

2012-08-10 02:58:11

The work is a key step toward 'universal' vaccine and therapies against flu A team led by scientists at The Scripps Research Institute and Crucell Vaccine Institute in the Netherlands describes three human antibodies that provide broad protection against Influenza B virus strains. The same team had previously reported finding broadly neutralizing antibodies against Influenza A strains. The isolation of the new broadly neutralizing antibodies, which was reported the journal Science's...

2012-08-08 02:28:10

SAN DIEGO, Aug. 8, 2012 /PRNewswire/ -- AnaptysBio, Inc., a privately held therapeutic antibody company, today announced the addition of Andrew J. McKnight, Ph.D. as Senior Director, Target Biology. Dr. McKnight comes to AnaptysBio with extensive experience in the design and development of novel therapeutic antibodies across a variety of therapeutic areas. Working together with David J. King, Ph.D., AnaptysBio's chief scientific officer, Dr. McKnight will be leading the advancement of...